دورية أكاديمية
أعرض في EDS

Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.

التفاصيل البيبلوغرافية
العنوان: Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
المؤلفون: Bissett C; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. cameron.bissett@linacre.ox.ac.uk., Belij-Rammerstorfer S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Ulaszewska M; Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Smith H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Kailath R; Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Morris S; Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Powers C; Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Sebastian S; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Sharpe HR; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Allen ER; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Wang Z; Department of Infectious Disease, Imperial College London, London, UK., Cunliffe RF; Department of Infectious Disease, Imperial College London, London, UK., Sallah HJ; Department of Infectious Disease, Imperial College London, London, UK., Spencer AJ; School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, Australia., Gilbert S; Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Tregoning JS; Department of Infectious Disease, Imperial College London, London, UK., Lambe T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
المصدر: NPJ vaccines [NPJ Vaccines] 2024 Jun 26; Vol. 9 (1), pp. 118. Date of Electronic Publication: 2024 Jun 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Nature in partnership with the Sealy Center for Vaccine Development Country of Publication: England NLM ID: 101699863 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-0105 (Electronic) Linking ISSN: 20590105 NLM ISO Abbreviation: NPJ Vaccines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Springer Nature in partnership with the Sealy Center for Vaccine Development, [2016]-
مستخلص: Although licensed vaccines against influenza virus have been successful in reducing pathogen-mediated disease, they have been less effective at preventing viral infection of the airways and current seasonal updates to influenza vaccines do not always successfully accommodate viral drift. Most licensed influenza and recently licensed RSV vaccines are administered via the intramuscular route. Alternative immunisation strategies, such as intranasal vaccinations, and "prime-pull" regimens, may deliver a more sterilising form of protection against respiratory viruses. A bivalent ChAdOx1-based vaccine (ChAdOx1-NP + M1-RSVF) encoding conserved nucleoprotein and matrix 1 proteins from influenza A virus and a modified pre-fusion stabilised RSV A F protein, was designed, developed and tested in preclinical animal models. The aim was to induce broad, cross-protective tissue-resident T cells against heterotypic influenza viruses and neutralising antibodies against RSV in the respiratory mucosa and systemically. When administered via an intramuscular prime-intranasal boost (IM-IN) regimen in mice, superior protection was generated against challenge with either RSV A, Influenza A H3N2 or H1N1. These results support further clinical development of a pan influenza & RSV vaccine administered in a prime-pull regimen.
(© 2024. The Author(s).)
References: Nat Biotechnol. 2013 Jul;31(7):647-52. (PMID: 23728362)
J Immunol. 2011 Apr 1;186(7):4331-9. (PMID: 21357542)
Emerg Microbes Infect. 2022 Dec;11(1):1890-1899. (PMID: 35775819)
EBioMedicine. 2023 Apr;90:104523. (PMID: 36933409)
Front Immunol. 2021 Nov 03;12:763912. (PMID: 34804053)
J Immunol. 2023 May 1;210(9):1257-1271. (PMID: 36881867)
Front Immunol. 2019 Jul 17;10:1605. (PMID: 31379823)
Sci Immunol. 2017 Jun 2;2(12):. (PMID: 28783656)
Nat Commun. 2015 Sep 03;6:8143. (PMID: 26333350)
Clin Vaccine Immunol. 2015 Dec 16;23(3):189-95. (PMID: 26677198)
Mol Ther. 2014 Mar;22(3):668-674. (PMID: 24374965)
Antiviral Res. 2018 Nov;159:95-103. (PMID: 30290196)
Hum Vaccin Immunother. 2014;10(4):1047-56. (PMID: 24513666)
J Virol. 2011 Aug;85(15):7788-96. (PMID: 21613394)
Biotechnol Bioeng. 2012 Mar;109(3):719-28. (PMID: 22252512)
J Virol. 2006 Dec;80(23):11756-66. (PMID: 16971435)
Vaccines (Basel). 2021 Nov 24;9(12):. (PMID: 34960128)
Front Immunol. 2018 Jan 31;9:126. (PMID: 29445377)
J Virol. 1996 May;70(5):2852-60. (PMID: 8627759)
Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989)
Immunohorizons. 2021 Feb 3;5(2):59-69. (PMID: 33536235)
Vaccine. 2016 Mar 4;34(10):1252-8. (PMID: 26827663)
Infect Immun. 1983 Oct;42(1):81-7. (PMID: 6352505)
Immunol Cell Biol. 2016 Nov;94(10):949-954. (PMID: 27502143)
Cleve Clin J Med. 2003 Sep;70(9):801-6. (PMID: 14518575)
Science. 2022 Nov 25;378(6622):eabo2523. (PMID: 36302057)
Sci Immunol. 2022 Oct 28;7(76):eadd4853. (PMID: 35857583)
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24. (PMID: 21586636)
Nat Commun. 2015 Dec 21;6:10224. (PMID: 26687547)
EBioMedicine. 2016 Jun;8:277-290. (PMID: 27428437)
Influenza Other Respir Viruses. 2021 Jul;15(4):539-551. (PMID: 33764693)
J Biomed Sci. 2013 Mar 21;20:19. (PMID: 23517052)
J Allergy Clin Immunol. 2022 Jul;150(1):1-11. (PMID: 35569567)
Curr Opin Immunol. 2023 Feb;80:102278. (PMID: 36565508)
NPJ Vaccines. 2017 Mar 8;2:7. (PMID: 29021918)
Vaccine. 2020 Sep 3;38(39):6088-6095. (PMID: 32718816)
JCI Insight. 2023 Jun 8;8(11):. (PMID: 37159271)
Sci Transl Med. 2021 Aug 18;13(607):. (PMID: 34315826)
Immunol Cell Biol. 2022 Jan;100(1):49-60. (PMID: 34687553)
PLoS One. 2010 Oct 04;5(10):e13162. (PMID: 20976273)
Nat Commun. 2021 Nov 26;12(1):6871. (PMID: 34836955)
NPJ Vaccines. 2022 Jun 28;7(1):71. (PMID: 35764661)
Ther Adv Vaccines Immunother. 2019 Feb 07;7:2515135519826481. (PMID: 30793097)
J Gen Virol. 2016 Sep;97(9):2104-2116. (PMID: 27260213)
Vaccine. 2017 Jan 11;35(3):469-480. (PMID: 27908639)
Eur J Immunol. 2006 May;36(5):1136-44. (PMID: 16619288)
Lancet Microbe. 2022 Jan;3(1):e11-e20. (PMID: 34751259)
PLoS One. 2019 Apr 15;14(4):e0215321. (PMID: 30986224)
J Virol. 2011 Jun;85(12):5782-93. (PMID: 21471228)
PLoS One. 2012;7(7):e40385. (PMID: 22808149)
Front Immunol. 2022 Jun 14;13:841471. (PMID: 35774800)
Front Immunol. 2019 Aug 21;10:2005. (PMID: 31497029)
J Vis Exp. 2012 Aug 01;(66):3960. (PMID: 22871688)
Mol Ther Methods Clin Dev. 2015 May 20;2:15018. (PMID: 26015988)
Sci Rep. 2021 Sep 20;11(1):18641. (PMID: 34545126)
J Virol. 2023 Nov 30;97(11):e0164622. (PMID: 37916834)
Science. 2013 May 31;340(6136):1113-7. (PMID: 23618766)
Virol J. 2013 Jun 07;10:183. (PMID: 23742026)
Vaccines (Basel). 2015 Apr 24;3(2):373-89. (PMID: 26343192)
Lancet Infect Dis. 2022 Jun;22(6):857-866. (PMID: 35305317)
Open Forum Infect Dis. 2023 Jan 12;10(1):ofac693. (PMID: 36655191)
J Infect Dis. 2020 Aug 4;222(5):807-819. (PMID: 31740938)
Vaccine. 2021 Jul 5;39(30):4063-4071. (PMID: 34140172)
J Virol. 2012 Dec;86(23):13016-24. (PMID: 23015695)
Front Microbiol. 2018 Feb 06;9:123. (PMID: 29467737)
J Infect Dis. 2022 Dec 28;227(1):50-60. (PMID: 36281651)
Nat Commun. 2023 Dec 5;14(1):8053. (PMID: 38052824)
J Infect Dis. 2024 Feb 14;229(2):346-354. (PMID: 37493269)
Eur J Immunol. 2022 Jun;52(6):936-945. (PMID: 35304741)
Sci Immunol. 2021 Dec 10;6(66):eabj5129. (PMID: 34890255)
Vaccine. 1999 Aug 20;18(1-2):82-8. (PMID: 10501238)
J Infect Dis. 2017 May 15;215(10):1527-1535. (PMID: 28368530)
Nat Rev Immunol. 2019 Jun;19(6):383-397. (PMID: 30837674)
Front Immunol. 2015 Dec 16;6:628. (PMID: 26734002)
JCI Insight. 2016 Jul 7;1(10):. (PMID: 27468427)
Lancet Infect Dis. 2023 Aug;23(8):956-964. (PMID: 37060917)
NPJ Vaccines. 2022 Dec 21;7(1):171. (PMID: 36543806)
J Immunol. 2016 Jun 15;196(12):5014-23. (PMID: 27183611)
PLoS One. 2011;6(7):e21823. (PMID: 21789184)
Front Immunol. 2020 Jul 17;11:1507. (PMID: 32765520)
Nat Struct Mol Biol. 2016 Sep;23(9):811-820. (PMID: 27478931)
Front Immunol. 2019 Mar 22;10:548. (PMID: 30967872)
Annu Rev Immunol. 2016 May 20;34:575-608. (PMID: 27168245)
J Exp Med. 2010 Jun 7;207(6):1153-60. (PMID: 20457758)
Science. 2013 Nov 1;342(6158):592-8. (PMID: 24179220)
Infect Immun. 1984 Feb;43(2):756-8. (PMID: 6363300)
J Immunol. 2006 Nov 1;177(9):6263-70. (PMID: 17056556)
Viruses. 2021 Aug 27;13(9):. (PMID: 34578289)
معلومات مُعتمدة: MC_PC_18059 RCUK | Medical Research Council (MRC)
تواريخ الأحداث: Date Created: 20240626 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11208422
DOI: 10.1038/s41541-024-00912-1
PMID: 38926455
قاعدة البيانات: MEDLINE
الوصف
تدمد:2059-0105
DOI:10.1038/s41541-024-00912-1